These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Villa LL Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241 [TBL] [Abstract][Full Text] [Related]
3. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279 [TBL] [Abstract][Full Text] [Related]
4. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Paavonen J; Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868 [TBL] [Abstract][Full Text] [Related]
5. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546 [TBL] [Abstract][Full Text] [Related]
6. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Jenkins D Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221 [TBL] [Abstract][Full Text] [Related]
7. Cervical cancer prevention in the human papilloma virus vaccine era. Ghazal-Aswad S Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904 [TBL] [Abstract][Full Text] [Related]
8. Introducing human papillomavirus vaccines - questions remain. Paavonen J; Lehtinen M Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882 [TBL] [Abstract][Full Text] [Related]
9. Correlating immunity with protection for HPV infection. Frazer I Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240 [TBL] [Abstract][Full Text] [Related]
10. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515 [TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950 [TBL] [Abstract][Full Text] [Related]
12. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control]. Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976 [TBL] [Abstract][Full Text] [Related]
13. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097 [TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus, cervical cancer, and the vaccines. Tovar JM; Bazaldua OV; Vargas L; Reile E Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. Agarossi A; Ferrazzi E; Parazzini F; Perno CF; Ghisoni L J Med Virol; 2009 Mar; 81(3):529-35. PubMed ID: 19152401 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Bonanni P; Boccalini S; Bechini A Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Bhatla N; Lal N; Bao YP; Ng T; Qiao YL Vaccine; 2008 Jun; 26(23):2811-7. PubMed ID: 18450340 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic HPV vaccination for women over 18 years of age. Adams M; Jasani B; Fiander A Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838 [TBL] [Abstract][Full Text] [Related]
19. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Wise LD; Wolf JJ; Kaplanski CV; Pauley CJ; Ledwith BJ Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):561-72. PubMed ID: 19025783 [TBL] [Abstract][Full Text] [Related]
20. HPV vaccination catch up program - utilisation by young Australian women. Weisberg E; Bateson D; McCaffery K; Skinner SR Aust Fam Physician; 2009; 38(1-2):72-6. PubMed ID: 19283241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]